Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

被引:0
作者
Li, Yimeng [1 ]
Hsu, Sylvia H. [2 ]
Wang, Rong [1 ]
Theprungsirikul, Poy [3 ]
Neparidze, Natalia [3 ]
Chang, Su-Hsin [4 ]
Wang, Shi-Yi [1 ]
机构
[1] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St,POB 208034, New Haven, CT 06520 USA
[2] York Univ, Schulich Sch Business, Toronto, ON, Canada
[3] Yale Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06520 USA
[4] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO USA
关键词
BMI; Obesity; Systematic review; Gender; Race; TERM-FOLLOW-UP; NEWCASTLE-OTTAWA SCALE; BODY-MASS INDEX; MALIGNANT-TRANSFORMATION; LONG-TERM; SIGNIFICANCE MGUS; RISK; QUALITY; PREVALENCE; PROGNOSIS;
D O I
10.1016/j.clml.2024.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of multiple myeloma (MM). Evidence suggested old age, black race, male gender, and obesity as risk factors for MGUS development; however, whether they are associated with an increased risk of progression to MM among patients with MGUS is unclear. A systematic search of PUBMED and EMBASE for cohort studies investigating the association between age/race/gender/obesity and progression to MM. We used the Newcastle-Ottawa Scale (NOS) to assess the methodologic quality of the included studies. Summary risk ratios were calculated using random-effects models. We identified 24 publications, of which 17 articles were included in the main analyses. Overall, the quality of the studies was fair (mean NOS = 5.5). Our meta-analyses showed that old age was positively associated with the risk of the MGUS-MM progression (risk ratio: 2.38; 95% confidence interval [CI] 1.59-3.57), while race was not statistically significantly associated with the risk (blacks vs whites: 1.09; 95% CI: 0.77-1.54). Males had a lower risk of MGUS-MM progression, compared to females (risk ratio: 0.70; 95% CI 0.50-1.0; P -value = .048). High body mass index was significantly associated with an increased risk of MGUS-MM progression (risk ratio: 1.32; 95% CI 1.12-1.57). Based on extant research, old age, female sex, and obesity may be implicated in MGUS-MM progression. However, several studies which found an insignificant association between age/gender and progression did not report the risk estimates. Publication bias exists and our risk estimates may be overestimated. More studies are warranted to confirm our findings.
引用
收藏
页码:e222 / e231
页数:10
相关论文
共 54 条
  • [21] Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study
    Ji, Mengmeng
    Shih, Yi-Hsuan
    Huber, John H.
    Wang, Mei
    Feuer, Eric J.
    Etzioni, Ruth
    Wang, Shi-Yi
    Chang, Su-Hsin
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (12) : 1690 - 1697
  • [22] Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance
    Ji, Mengmeng
    Huber, John H.
    Schoen, Martin W.
    Sanfilippo, Kristen M.
    Colditz, Graham A.
    Wang, Shi-Yi
    Chang, Su-Hsin
    [J]. JAMA ONCOLOGY, 2023, 9 (09) : 1293 - 1295
  • [23] Multiple myeloma epidemiology and survival: A unique malignancy
    Kazandjian, Dickran
    [J]. SEMINARS IN ONCOLOGY, 2016, 43 (06) : 676 - 681
  • [24] Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
    Kleinstern, Geffen
    Larson, Dirk R.
    Allmer, Cristine
    Norman, Aaron D.
    Muntifering, Grace
    Sinnwell, Jason
    Visram, Alissa
    Rajkumar, Vincent
    Dispenzieri, Angela
    Kyle, Robert A.
    Slager, Susan L.
    Kumar, Shaji
    Vachon, Celine M.
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [25] Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study
    Kuwabara, Chihiro
    Sakuma, Yukie
    Kume, Ayaka
    Tamura, Yuri
    Shimizu, Ryo
    Iwai, Rie
    Ishii, Akihiro
    Tanaka, Hiroaki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) : 154 - 161
  • [26] Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Remstein, ED
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, LJ
    [J]. BLOOD, 2003, 102 (10) : 3759 - 3764
  • [27] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569
  • [28] Prevalence of monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Larson, DR
    Plevak, MF
    Offord, JR
    Dispenzieri, A
    Katzmann, JA
    Melton, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) : 1362 - 1369
  • [29] Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
    Kyle, Robert A.
    Larson, Dirk R.
    Therneau, Terry M.
    Dispenzieri, Angela
    Kumar, Shaji
    Cerhan, James R.
    Rajkumar, S. Vincent
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (03) : 241 - 249
  • [30] Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
    Landgren, O
    Gridley, G
    Turesson, I
    Caporaso, NE
    Goldin, LR
    Baris, D
    Fears, TR
    Hoover, RN
    Linet, MS
    [J]. BLOOD, 2006, 107 (03) : 904 - 906